BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

April 25, 2025

Announcement no. 13

                                                                        

Managers’ transactions

In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them.

1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameJens Due Olsen
2 Reason for the notification 
a)   Position/statusChair of the Board of Directors of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 2,984,629
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue
  
1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameHenrik Juul
2 Reason for the notification 
a)   Position/statusVice Chair of the Board of Directors of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
a)   Nature of the transactionSubscription of new shares in connection with private placement
b)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 746,157
c)   Aggregated informationn/a





d)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
e)   Place of the transactionOutside a trading venue
  
1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NamePeter Mørch Eriksen
2 Reason for the notification 
a)   Position/statusChief Executive Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 373,078
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue



1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameGry Husby Larsen
2 Reason for the notification 
a)   Position/statusChief Legal Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 186,539
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue



1 Details of the person discharging managerial responsibilities/person closely associated 
a)   NameNiels Høy Nielsen
2 Reason for the notification 
a)   Position/statusChief Financial Officer of BioPorto A/S
b)   Initial notification/AmendmentInitial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a)   NameBioPorto A/S
b)   LEI5299004SWFL5JAN4W830
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a)   Description of the financial instrument, type of instrument



Identification code
Shares



ISIN code DK0063969092 (to be merged with permanent ISIN code DK0011048619)
b)   Nature of the transactionSubscription of new shares in connection with private placement
c)   Price(s) and volume(s)Price: DKK 1.3402, Volume: 186,539
d)   Aggregated informationn/a





e)   Date of the transaction2025-04-25 at 06:12 a.m. UTC (08:12 a.m. CEST)
f)   Place of the transactionOutside a trading venue

To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on /investor-contact/.

For further information, please contact:

Hanne S. Foss, Head of Investor Relations, BioPorto, , C:

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit .

Attachment



EN
25/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

BioPorto A/S udnævner CFO

BioPorto A/S udnævner CFO 9. februar, 2026Meddelelse nr. 2 BioPorto A/S udnævner CFO BioPorto A/S (BioPorto) (CPH:BIOPOR) annoncerede i dag udnævnelsen af Klaus Juhl Wulff som ny Executive Vice President (EVP) og Chief Financial Officer (CFO) samt medlem af Executive Management-teamet senest pr. 1. maj 2026. Klaus Juhl Wulff er en højt kvalificeret leder med mere end 20 års erfaring inden for finans, drift, M&A og kapitalmarkeder. Han kommer til BioPorto fra AquaPorin A/S, hvor han var CFO fra 2022. Før dette har Klaus Juhl Wulff fungeret som CFO i forskellige virksomheder. Klaus Juhl W...

 PRESS RELEASE

BioPorto A/S Appoints Chief Financial Officer

BioPorto A/S Appoints Chief Financial Officer February 9, 2026Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), and member of the Executive Management team as of latest May 1st, 2026. Klaus Juhl Wulff is a highly skilled leader with more than 20 years of experience in finance, operations, M&A and capital markets. He joins BioPorto from AquaPorin A/S, where he served as CFO from 2022. Prior to this, Klaus Juhl...

 PRESS RELEASE

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, fin...

BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering  5. februar 2026Meddelelse nr. 1 BioPorto leverer foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopdatering                                                                         KØBENHAVN, DANMARK, 5. februar, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH:BIOPOR), annoncerede i dag foreløbige, ureviderede finansielle tal for 2025, finansiel guidance for 2026 og en forretningsopd...

 PRESS RELEASE

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financ...

BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update  February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update                                                                         COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update.                       ...

 PRESS RELEASE

Ændringer i selskabets Direktion

Ændringer i selskabets Direktion 11. december 2025 Meddelelse nr. 29 Ændringer i selskabets Direktion KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. december 2025 (GLOBE NEWSWIRE) – BioPorto A/S ("BioPorto") (CPH:BIOPOR) meddelte i dag, at Niels Høy Nielsen har opsagt sin stilling som CFO for BioPorto for at tiltræde en CFO-stilling i et andet selskab. "Jeg har værdsat det tætte samarbejde med Niels i de sidste par måneder, siden jeg tiltrådte min stilling i BioPorto. Niels har ydet vigtige bidrag til virksomheden og jeg ønsker ham alt det bedste i hans fremtidige stilling," sagde Carsten B...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch